Recent evidence suggests that mediators involved in the FcεRI signaling pathways may be used as potential pharmaceutical therapeutic targets for AD-associated pruritus in the future, by modulating the crosstalk between neuroimmune, immune and skin cells. This evidence concerns the gene FCER1A and Pruritus.